MG
DSGN icon

Michael Gelband’s Design Therapeutics DSGN Stock Holding History

Michael Gelband’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Buy
+41,286
New +$515K ﹤0.01% 1189
2023
Q3 		– Sell
-265,384
Closed -$1.67M – 1794
2023
Q2 		$1.67M Buy
265,384
+109,246
+70% +$669K 0.01% 884
2023
Q1 		$901K Buy
156,138
+105,407
+208% +$788K 0.01% 1175
2022
Q4 		$521K Sell
50,731
-1,110
-2% -$15K 0.01% 1158
2022
Q3 		$867K Buy
+51,841
New +$1.03M 0.01% 1164

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's DSGN Position: Q2 2026 in Review

Michael Gelband opened a new position in Design Therapeutics (DSGN) in Q2 2026: 41,286 shares worth $597K. The stake represents ﹤0.01% of the portfolio and ranks #1189 among its holdings. This is a return to the name: Michael Gelband previously reported a position in DSGN as recently as Q2 2023.

Michael Gelband first reported a position in DSGN in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.67M in Q2 2023. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Michael Gelband held 41,286 shares of Design Therapeutics worth $597K as of Q2 2026.
  • Design Therapeutics was a new Michael Gelband position in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1189 holding.
  • Michael Gelband first reported a position in Design Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • Michael Gelband's Design Therapeutics position peaked at $1.67M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.